Tenax Therapeutics (TENX) Preferred Stock Liabilities (2012)

Tenax Therapeutics (TENX) reported Preferred Stock Liabilities of $429978.0 for Q4 2012, down 78.89% sequentially from $2.0 million in Q3 2012.

Tenax Therapeutics (TENX) Preferred Stock Liabilities (2012) Analysis & Trends

Tenax Therapeutics (TENX) has 1 years of Preferred Stock Liabilities data on file, last reported at $429978.0 in Q4 2012.

For the quarter ending Q4 2012, Preferred Stock Liabilities changed N/A year-over-year to $429978.0; the trailing twelve-month figure through Oct 2012 stood at $429978.0 (changed N/A YoY), and the FY2012 full-year result was $1.2 million, changed N/A from the prior year.
Preferred Stock Liabilities eased to $429978.0 in Q4 2012, from $2.0 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $3.9 million in Q1 2012 to a low of $429978.0 in Q4 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Tenax Therapeutics	67,856.40	67,856.40	-	-

Download Data